声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。11月12日,阿斯利康宣布了三件大事:01上调全年业绩指引11月12日,阿斯利康公布2024年三季报:前三个季度收入391.82亿美元,同比增长19%(按固定汇率计算,下同),核心每股收益6.12美元,同比增长11%;其中第三季度收入135.65亿美元,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.